NR3C1 and ocular melanoma: Using the glucocorticoid receptor agonist fluticasone, which was predicted to increase OM and decrease CaP-induced SMC phenotype, we observed increased ECM mineralization when used as a dexamethasone substitute in OM and no effect on CaP-calcified iSMCs (Supplementary Figures 7C,D).